Cargando…
Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
Recent data from a phase 3 trial have shown that the addition of immunotherapy to neoadjuvant chemotherapy improves event-free survival in patients with non-small-cell lung cancer (NSCLC). This is the first positive phase 3 trial in this setting, although several phase 3 trials are currently investi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537502/ https://www.ncbi.nlm.nih.gov/pubmed/36212602 http://dx.doi.org/10.5306/wjco.v13.i9.758 |